This medication is used to treat Alzheimer's disease. It is thought to work by decreasing a certain substance (amyloid beta) that builds up in the brain of a person with Alzheimer's disease. Donanemab ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. Kisunla is given as an intravenous (IV) infusion by a doctor or other healthcare professional. Note: ...

Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease with more in development. A potential and serious side effect of anti-amyloid ...

The National Institute for Health and Care Excellence (NICE) has recommended that donanemab not be approved for use on the NHS on the day that the Medicines and Healthcare products Regulatory Agency ...

In the mountains of northwestern Colombia, thousands of members of extended families carry a single genetic mutation that all but guarantees they will develop Alzheimer’s disease before age 50. For ...

Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...

The FDA typically follows the recommendations of its advisory panels but is not required to do so. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind ...

INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly ...